Mutation-Targeted AML Strategies
Please complete Pre-test
Chapter 1 of 1
Release Date: November 4, 2021
Expiration Date: November 4, 2022
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Explore strategies for providing mutation-targeted therapy in acute myeloid leukemia (AML). In this activity, Dr. Fathi will discuss approved and emerging treatments that have shown efficacy for established AML mutations, including IDH1/2, FLT3, and TP53.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Explore contemporary therapeutic options for AML patients with FLT3 mutations
- Identify optimal therapy for AML patients with IDH1/2 mutations
- Review current evidence for the optimal management of AML patients with TP53 mutations
- Analyze novel methods of targeting potential for combination therapies
Mutation-Targeted AML Strategies – Amir T. Fathi, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 04, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor in Medicine
Harvard Medical School
Dr. Amir Fathi graduated summa cum laude from Yale University with a BS degree in molecular, cellular, and developmental biology. He went on to receive his medical degree with honors at the Yale School of Medicine. He also has a master’s degree in epidemiology from Harvard School of Public Health. Dr. Fathi completed his residency training in internal medicine at Massachusetts General Hospital (MGH), and fellowships in both hematology and medical oncology at Johns Hopkins Hospital. He is the Program Director of the Center for Leukemia at the Massachusetts General Hospital Cancer Center; he is also an Associate Professor in Medicine at Harvard Medical School.
Dr. Fathi has presented at national meetings of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH), spoken at national academic and educational meetings, and has served on national committees that establish guidelines for the management of acute and chronic leukemias. As faculty at the MGH Cancer Center and Harvard Medical School, Dr. Fathi provides clinical care, supervises trainees, administers a busy clinic, and as the director of clinical research in leukemia, is the lead investigator on numerous clinical trials investigating novel treatments in acute leukemias. His other interests focus on developing translational projects to discover new targets for therapy.
Outcomes for patients with acute myeloid leukemia (AML) continue to be poor despite incremental advances in treatment and supportive care over the last 30 years. Although most patients respond to initial treatment, the majority eventually relapse and many succumb to their disease. Therefore, new and innovative approaches are desperately needed to significantly improve outcomes. As a clinician-scientist with a deep interest in developing novel therapies for AML, Dr. Fathi endeavors to provide outstanding clinical care, teaching, and mentoring, while also conducting translational projects, retrospective research, and clinical trials, with the overarching goal improving the health and outcomes of patients with bone marrow malignancies.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]medicaled.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.
©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-042-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Amir Fathi has relevant financial relationships related to advisory activities and consulting from AbbVie Inc., Agios, Inc. (now Servier Laboratories), Amgen Inc., Astellas Pharma US, Inc., Blueprint Medicines, Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Foghorn Therapeutics, Genentech, Inc., Ipsen, Kite Pharma, Kura Oncology, Inc., MorphoSys, Pfizer Inc., Seattle Genetics, Inc., Takeda Oncology, and Trillium Therapeutics Inc., as well as clinic trial support from Abbvie, Agios (now Servier), and Celgene Corporation ‒ A Bristol-Myers Squibb Company.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.